The combination of aripiprazole and selective serotonin reuptake inhibitor (SSRI) antidepressants [citalopram, escitalopram, sertraline] in the acute treatment of psychotic major depression: Efficacy and tolerability.

Trial Profile

The combination of aripiprazole and selective serotonin reuptake inhibitor (SSRI) antidepressants [citalopram, escitalopram, sertraline] in the acute treatment of psychotic major depression: Efficacy and tolerability.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2012

At a glance

  • Drugs Aripiprazole; Citalopram; Escitalopram; Sertraline
  • Indications Psychotic affective disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Aug 2012 Actual patient number changed from 35 to 16 as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Primary endpoint identified as clinical response as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top